27349-66-2Relevant articles and documents
Cooperative Interactions in the Second Coordination Sphere of Pyridazine/Pyridine Containing Polyazaheterocyclic Iron(II) Complexes Favor Protonation
Hammoud, Ahmad,Nshimyumuremyi, Jean-Boris,Bourotte, Jérémie,Lucaccioni, Fabio,Robeyns, Koen,D?rtu, Marinela M.,Garcia, Yann,Singleton, Michael L.
, p. 3253 - 3263 (2018/07/31)
The new pyridazine containing iron complexes, [N,N,N′,N′-tetrakis(3-pyridazylmethyl)propylenediamine]iron(II)(PF6)2 (1) and [N,N′-bis(2-pyridazylmethyl)-N,N′-bis(2-pyridylmethyl)propylenediamine]iron(II) (PF6)2 (2) were synthesized and their reactivity towards protonation was compared to that of the analogous tetrapyridine complex [N,N,N′,N′-tetrakis(2-pyridylmethyl)propylenediamine]iron(II)(PF6)2 (3). The solution and solid-state structures were confirmed by NMR and X-ray crystallographic studies. For 1–3, the ligands bind in a hexadentate fashion giving similar octahedral structures with an N6 coordination environment. Across the series, the increasing number of pyridazines has only modest effects on the spectroscopic and electrochemical properties of the metal. Nevertheless, their reactivity towards protonation is drastically different. While 2 and 3 decompose in the presence of strong acids, 1 is able to be stably protonated as a result of cooperative second sphere interactions.
Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
-
Page column 50-51, (2010/02/06)
Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R1 is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR5R6 or a N-linked heterocyclic group; (CH2)nHet or (CH2)nAr; R2 is C1 to C6 alkyl; R3 is C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy; R4 is SO2NR7R8; R5 and R6 are each independently selected from H and C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2; H is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, inter alia, male erectile dysfunction and female sexual dysfunction.
